$ICAD
ICAD INC Stock $icad

$icad Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923014560 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$5.865M	$5.778M	$6.489M
YoY Change	-22.57%	-23.2%	-16.89%
Cost Of Revenue	$1.516M	$1.648M	$1.853M
YoY Change	-27.26%	-25.46%	-11.93%
Gross Profit	$4.349M	$4.130M	$4.636M
YoY Change	-20.8%	-22.25%	-18.72%
Gross Profit Margin	74.15%	71.48%	71.44%
Selling, General & Admin	$4.944M	$5.719M	$6.112M
YoY Change	-19.96%	-11.96%	-16.74%
% of Gross Profit	113.68%	138.47%	131.84%
Research & Development	$1.263M	$2.281M	$1.813M
YoY Change	-46.64%	0.26%	-25.97%
% of Gross Profit	29.04%	55.23%	39.11%
Depreciation & Amortization	$108.0K	$78.00K	$117.0K
YoY Change	-20.0%	-43.88%	-15.83%
% of Gross Profit	2.48%	1.89%	2.52%
Operating Expenses	$6.272M	$8.055M	$7.969M
YoY Change	-27.11%	-8.82%	-19.11%
Operating Profit	-$1.923M	-$3.925M	-$3.333M
YoY Change	-38.25%	11.44%	-19.65%
Interest Expense	$0.00	$0.00	$122.0K
YoY Change		-100.0%	3966.67%
% of Operating Profit
Other Income/Expense, Net	$177.0K	$152.0K	$0.00
YoY Change	-4525.0%	-1269.23%
Pretax Income	-$1.746M	-$3.773M	-$3.211M
YoY Change	-44.0%	6.46%	-22.53%
Income Tax	$4.000K	$5.000K	-$116.0K
% Of Pretax Income
Net Earnings	-$1.750M	-$3.778M	-$3.095M
YoY Change	-43.87%	6.57%	-25.35%
Net Earnings / Revenue	-29.84%	-65.39%	-47.7%
Basic Earnings Per Share	-$0.07	-$0.15
Diluted Earnings Per Share	-$0.07	-$0.15	-$0.12
COMMON SHARES
Basic Shares Outstanding	25.45M	25.45M	25.45M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.04M	$19.66M	$21.31M
YoY Change	-29.96%	-34.01%	-37.83%
Cash & Equivalents	$19.04M	$19.66M	$21.31M
Short-Term Investments
Other Short-Term Assets	$1.461M	$1.654M	$2.641M
YoY Change	-5.98%	-13.67%	147.52%
Inventory	$4.248M	$4.866M	$5.389M
Prepaid Expenses
Receivables	$5.747M	$7.381M	$8.898M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$31.34M	$34.20M	$38.24M
YoY Change	-30.83%	-28.65%	-23.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.471M	$1.153M	$1.074M
YoY Change	51.96%	-36.16%	21.77%
Goodwill	$8.362M	$8.362M	$8.362M
YoY Change	0.0%		0.0%
Intangibles	$388.0K	$436.0K	$482.0K
YoY Change	-33.9%		-29.43%
Long-Term Investments
YoY Change
Other Assets	$162.0K	$166.0K	$12.39M
YoY Change	194.55%	201.82%	22427.27%
Total Long-Term Assets	$13.50M	$13.32M	$13.46M
YoY Change	3.23%	22.04%	13.29%
TOTAL ASSETS
Total Short-Term Assets	$31.34M	$34.20M	$38.24M
Total Long-Term Assets	$13.50M	$13.32M	$13.46M
Total Assets	$44.83M	$47.52M	$51.71M
YoY Change	-23.21%	-19.25%	-16.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$857.0K	$1.888M	$1.973M
YoY Change	-61.01%	-29.58%	-29.0%
Accrued Expenses	$4.363M	$4.213M	$4.681M
YoY Change	-17.23%	-29.96%	-17.03%
Deferred Revenue	$6.027M	$6.211M	$6.216M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.89M	$12.88M	$13.45M
YoY Change	-16.3%	-10.93%	-10.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.761M	$2.922M	$3.345M
YoY Change	-13.15%	367.52%	373.13%
Total Long-Term Liabilities	$2.761M	$2.922M	$3.345M
YoY Change	-13.15%	367.52%	373.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.89M	$12.88M	$13.45M
Total Long-Term Liabilities	$2.761M	$2.922M	$3.345M
Total Liabilities	$14.66M	$15.81M	$16.80M
YoY Change	-15.71%	4.75%	7.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$272.4M	-$270.6M	-$266.8M
YoY Change	4.82%		5.39%
Common Stock	$304.0M	$303.7M	$303.2M
YoY Change	0.56%		0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$1.415M
YoY Change			0.0%
Treasury Stock Shares			$185.8K
Shareholders Equity	$30.17M	$31.71M	$34.90M
YoY Change
Total Liabilities & Shareholders Equity	$44.83M	$47.52M	$51.71M
YoY Change	-23.21%	-19.25%	-16.86%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.750M	-$3.778M	-$3.095M
YoY Change	-43.87%	6.57%	-25.35%
Depreciation, Depletion And Amortization	$108.0K	$78.00K	$117.0K
YoY Change	-20.0%	-43.88%	-15.83%
Cash From Operating Activities	-$405.0K	-$1.528M	-$3.129M
YoY Change	-84.18%	-65.66%	102.26%
INVESTING ACTIVITIES
Capital Expenditures	$185.0K	$122.0K	$169.0K
YoY Change	-277.88%	-175.78%	-223.36%
Acquisitions
YoY Change
Other Investing Activities	-$36.00K
YoY Change
Cash From Investing Activities	-$221.0K	-$122.0K	-$169.0K
YoY Change	112.5%	-24.22%	23.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00	21.00K
YoY Change	-100.0%	-100.0%	-86.96%
NET CHANGE
Cash From Operating Activities	-405.0K	-$1.528M	-3.129M
Cash From Investing Activities	-221.0K	-$122.0K	-169.0K
Cash From Financing Activities	0.000	$0.00	21.00K
Net Change In Cash	-626.0K	-$1.650M	-3.277M
YoY Change	-76.09%	-63.2%	115.17%
FREE CASH FLOW
Cash From Operating Activities	-$405.0K	-$1.528M	-$3.129M
Capital Expenditures	$185.0K	$122.0K	$169.0K
Free Cash Flow	-$590.0K	-$1.650M	-$3.298M
YoY Change	-75.98%	-61.52%	133.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	922000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	922000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2151000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2135000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8980000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8932000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25446407
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25446407
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25260576
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25260576
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	185831
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	185831
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-09341
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0377419
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	98 Spit Brook Road, Suite 100
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Nashua
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NH
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	03062
CY2023Q1	dei	City Area Code CityAreaCode	603
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	882-5200
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	ICAD
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1415000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1415000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	31710000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25446407
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19663000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21313000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7381000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8898000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	4866000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5389000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2292000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2641000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	34202000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38241000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1153000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1074000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3200000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3361000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	55000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	69000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	436000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	482000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	8362000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8362000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	111000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	116000	usd
CY2023Q1	us-gaap	Assets Assets	47519000	usd
CY2022Q4	us-gaap	Assets Assets	51705000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1888000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1973000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4213000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4681000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	569000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	582000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6211000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6216000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12881000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13452000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2639000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2803000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	283000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	542000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	15809000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	16803000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	254000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	254000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	303485000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	302899000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270614000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266836000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34902000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47519000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51705000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5778000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7523000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1648000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2211000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	4130000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	5312000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2281000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2275000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2857000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3565000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2862000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2931000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	63000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8055000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8834000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3925000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3522000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	-0	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	9000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	150000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	152000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3773000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3544000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3545000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25261
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25160
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34902000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3778000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	31710000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	46517000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	60000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	655000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3545000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	43753000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3545000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	53000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	78000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	86000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	161000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	200000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	305000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	586000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	655000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	5000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1517000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1723000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-523000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	565000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-363000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-653000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-120000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-84000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-468000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-514000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-177000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-214000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-264000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	243000	usd
CY2023Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2250000	usd
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-904000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1528000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4449000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	122000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-122000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-161000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	60000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	126000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1650000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4484000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21313000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34282000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19663000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29798000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	9000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 13pt;"><b><i>Risk and Uncertainty </i></b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt;">On <em style="font: inherit;"> March </em><em style="font: inherit;">12,</em> <em style="font: inherit;">2020,</em> the World Health Organization declared COVID-<em style="font: inherit;">19</em> to be a pandemic. In an effort to contain and mitigate the spread of COVID-<em style="font: inherit;">19,</em> the United States and most countries of the world imposed some level of unprecedented restrictions such as travel bans and business closures which caused substantial reductions in economic activity. As a provider of devices and services to the health care industry, the Company believes its operations have been materially affected in all periods presented. While the worst of the disruptions appear to have subsided as of <em style="font: inherit;"> March 31, 2023, </em>the Company continues to be impacted by slowness in the overall economic recovery. The Company’s expected results for future periods could reflect a continuing negative impact from the COVID-<em style="font: inherit;">19</em> pandemic for similar or additional reasons.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt;">In late <em style="font: inherit;"> February 2022, </em>Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region has continued through <em style="font: inherit;"> March 31, 2023 </em>and beyond. Economic, civil, military and political uncertainty <em style="font: inherit;"> may </em>arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue <em style="font: inherit;"> may </em>experience military action and/or civil and political unrest; <em style="font: inherit;"> may </em>be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. While the impact to the Company has been limited to date, it is <em style="font: inherit;">not</em> possible to predict the potential outcome should the conflict expand and/or additional sanctions be imposed. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2023, </em>approximately 15% of the Company's revenue was derived from customers located outside the United States. </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 25pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5778000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5778000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5778000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7523000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7523000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7523000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	7381000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	8898000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	638000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	759000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6494000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6758000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6758000	usd
CY2023Q1	icad	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	5514000	usd
CY2023Q1	icad	Contract With Customer Liability Revenue Recognized During Period ContractWithCustomerLiabilityRevenueRecognizedDuringPeriod	5778000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6494000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3400000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1300000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1000000.0	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	800000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	213000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	101000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1802000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2892000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	5128000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3545000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25261
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25160
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2946470
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2894449
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3113000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2658000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	5651000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	262000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	262000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	4866000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5389000	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	216000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	232000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	549000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	846000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	848000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	749000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	685000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	172000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3849000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	641000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3208000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	569000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2639000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	541142
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	586000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	655000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M2D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0419	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0146	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.16
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.22
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2610992
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.54
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	541142
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.16
CY2023Q1	icad	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	204331
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.27
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2947803
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.44
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1619855
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.47
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1985026
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.44
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22833
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	4200000	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.28	pure
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	23	pure
CY2023Q1	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	100000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	76000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring		usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	76000	usd

Files In Submission

Name	View Source	Status
icad-20230331_cal.xml	Edgar Link	unprocessable
icad-20230331_lab.xml	Edgar Link	unprocessable
0001437749-23-014560-index-headers.html	Edgar Link	pending
0001437749-23-014560-index.html	Edgar Link	pending
0001437749-23-014560.txt	Edgar Link	pending
0001437749-23-014560-xbrl.zip	Edgar Link	pending
ex_493612.htm	Edgar Link	pending
ex_493613.htm	Edgar Link	pending
ex_493614.htm	Edgar Link	pending
ex_493615.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
icad-20230331.xsd	Edgar Link	pending
icad20230331_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
icad-20230331_def.xml	Edgar Link	unprocessable
icad-20230331_pre.xml	Edgar Link	unprocessable
icad20230331_10q_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICAD
ICAD INC Stock $icad

2023 Q2 Form 10-Q Financial Statement

#000143774923014560 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICAD ICAD INC Stock $icad

2023 Q2 Form 10-Q Financial Statement

#000143774923014560 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICAD
ICAD INC Stock $icad